Search results
Added:
3 years ago
Ideally biomarkers provide the clinician with assistance in one or more of: (i) diagnosis, (ii) prognosis, (iii) choice and titration of therapy, (iv) monitoring progression of disease and (v) assessing response to treatment. The best-established biomarkers in acute decompensated heart failure (ADHF) are the B-type natriuretic peptides (brain natriuretic peptide [BNP] and N-terminal of the…
View more
Added:
3 years ago
Natriuretic peptides (NPs) are well established in the diagnostic process of heart failure (HF). Low levels of NPs are particularly useful to exclude heart failure (HF). Numerous studies, predominantly in patients presenting with acute onset of symptoms suspected of HF, have convincingly shown the value of NPs in this regard. A meta-analysis published in 2015 clearly summarised the value of brain…
View more
SGLT2 Inhibition in Heart Failure: New Updates
Video Series
Added:
3 years ago
Although the first study on biomarker-guided therapy of chronic heart failure (HF) was published 15 years ago,1 there is still no real proof of the superiority of this approach as compared with standard therapy. The guidelines of the European Society of Cardiology simply state that: “several RCTs that evaluated natriuretic peptide-guided treatment (intensifying treatment in order to lower peptide…
View more
Added:
3 years ago
The National Institutes of Health Biomarkers Definitions Working Group define a biomarker as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”.1 Biomarkers have become increasingly important in current medical practice as they offer an easy way to either…
View more
Added:
1 year ago
ESC Congress 22 — In this short interview filmed on-site at the 2022 ESC Congress, we are joined by Prof Harald Sourij to discuss the findings of the EMMY trial (NCT03087773) on the impact of empagliflozin on cardiac function and biomarkers of heart failure in patients with acute myocardial infarction.
476 participants with acute MI were included in the trial, and were randomised to receive…
View more
Added:
1 year ago
In this short interview, Dr Pablo Garcia-Pavia (Hospital Universitario Puerta de Hierro Majadahonda, ES) shares the findings from the phase 3 study, HELIOS-A (NCT03759379).
The study, presented at Heart Failure 2022, investigated the efficacy and safety of vutrisiran (ALN-TTRSC02) in patients with hereditary transthyretin amyloidosis (hATTR amyloidosis).
Discussion Points
1. Vutrisiran
3. Study…
View more
Added:
1 year ago
Added:
2 years ago
Daniel Cheng Lee Pang
Author
